Abstract
Gain-of-function variants in some RAS–MAPK pathway genes, including PTPN11 and NRAS, are associated with RASopathies and/or acquired hematological malignancies, most notably juvenile myelomonocytic leukemia (JMML). With rare exceptions, the spectrum of germline variants causing RASopathies does not overlap with the somatic variants identified in isolated JMML. Studies comparing these variants suggest a stronger gain-of-function activity in the JMML variants. As JMML variants have not been identified as germline defects and have a greater impact on protein function, it has been speculated that they would be embryonic lethal. Here we identified three variants, which have previously only been identified in isolated somatic JMML and other sporadic cancers, in four cases with a severe pre- or neo-natal lethal presentation of Noonan syndrome. These cases support the hypothesis that these stronger gain-of-function variants are rarely compatible with life.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Tartaglia M, Gelb BD : Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms. Ann N Y Acad Sci 2010; 1214: 99–121.
Lee KA, Williams B, Roza K et al: PTPN11 analysis for the prenatal diagnosis of Noonan syndrome in fetuses with abnormal ultrasound findings. Clin Genet 2009; 75: 190–194.
Houweling AC, de Mooij YM, van der Burgt I, Yntema HG, Lachmeijer AM, Go AT : Prenatal detection of Noonan syndrome by mutation analysis of the PTPN11 and the KRAS genes. Prenat Diagn 2010; 30: 284–286.
Croonen EA, Nillesen WM, Stuurman KE et al: Prenatal diagnostic testing of the Noonan syndrome genes in fetuses with abnormal ultrasound findings. Eur J Hum Genet 2013; 21: 936–942.
Miller CA, Wilson RK, Ley TJ : Genomic landscapes and clonality of de novo AML. N Engl J Med 2013; 369: 1473.
Molteni CG, Te Kronnie G, Bicciato S et al: PTPN11 mutations in childhood acute lymphoblastic leukemia occur as a secondary event associated with high hyperdiploidy. Leukemia 2010; 24: 232–235.
Ricci C, Fermo E, Corti S et al: RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant. Clin Cancer Res 2010; 16: 2246–2256.
Hasle H : Malignant diseases in Noonan syndrome and related disorders. Horm Res 2009; 72 (Suppl 2): 8–14.
Strullu M, Caye A, Lachenaud J et al: Juvenile myelomonocytic leukaemia and Noonan syndrome. J Med Genet 2014; 51: 689–697.
Cirstea IC, Kutsche K, Dvorsky R et al: A restricted spectrum of NRAS mutations causes Noonan syndrome. Nat Genet 2010; 42: 27–29.
Runtuwene V, van Eekelen M, Overvoorde J et al: Noonan syndrome gain-of-function mutations in NRAS cause zebrafish gastrulation defects. Dis Model Mech 2011; 4: 393–399.
Bocchinfuso G, Stella L, Martinelli S et al: Structural and functional effects of disease-causing amino acid substitutions affecting residues Ala72 and Glu76 of the protein tyrosine phosphatase SHP-2. Proteins 2007; 66: 963–974.
Chan RJ, Feng GS : PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood 2007; 109: 862–867.
Tartaglia M, Martinelli S, Stella L et al: Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am J Hum Genet 2006; 78: 279–290.
Oliveira JB, Bidere N, Niemela JE et al: NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc Natl Acad Sci USA 2007; 104: 8953–8958.
De Filippi P, Zecca M, Lisini D et al: Germ-line mutation of the NRAS gene may be responsible for the development of juvenile myelomonocytic leukaemia. Br J Haematol 2009; 147: 706–709.
Tartaglia M, Niemeyer CM, Fragale A et al: Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003; 34: 148–150.
Pugh TJ, Kelly MA, Gowrisankar S et al: The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing. Genet Med 2014; 16: 601–608.
Kothiyal P, Cox S, Ebert J, Aronow BJ, Greinwald JH, Rehm HL : An overview of custom array sequencing. Curr Protoc Hum Genet/editorial board, Jonathan L Haines [et al] 2009; Chapter 7: Unit 7 17.
Forbes SA, Beare D, Gunasekaran P et al: COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 2014; 43: D805–D811.
Jain Ghai S, Keating S, Chitayat D : PTPN11 gene mutation associated with abnormal gonadal determination. Am J Med Genet Pt A 2011; 155A: 1136–1139.
Wang J, Liu Y, Li Z et al: Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner. Blood 2011; 118: 368–379.
Acknowledgements
We thank Partner's Personalized Medicine Laboratory of Molecular Medicine staff for excellent technical support.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
HM-S, DT, KAL, TEM and MSL are employed by non-profit, fee-for-service laboratories that offers genetic testing.
Additional information
Supplementary Information accompanies this paper on European Journal of Human Genetics website
Supplementary information
Rights and permissions
About this article
Cite this article
Mason-Suares, H., Toledo, D., Gekas, J. et al. Juvenile myelomonocytic leukemia-associated variants are associated with neo-natal lethal Noonan syndrome. Eur J Hum Genet 25, 509–511 (2017). https://doi.org/10.1038/ejhg.2016.202
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/ejhg.2016.202
This article is cited by
-
Combined HRAS and NRAS ablation induces a RASopathy phenotype in mice
Cell Communication and Signaling (2024)
